MEDIVATION, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Cash flows from operating activities:
Net income (loss)
Adjustments for non-cash operating items:
Stock-based compensation
Impairment of intangible assets
Loss on extinguishment of Convertible Notes
Amortization of debt discount and debt issuance costs
Depreciation on property and equipment
Asset impairment and other charges
Accretion of discount on securities
Excess tax benefits from stock-based compensation
Changes in deferred income taxes
Change in fair value of contingent purchase consideration
Amortization of deferred revenue
Release of valuation allowance for deferred income taxes
Other non-cash items
Changes in operating assets and liabilities:
Receivable from collaboration partners
Prepaid expenses and other current assets
Other assets
Other non-current assets
Accounts payable
Accrued expenses
Other current liabilities
Accrued expenses and other current liabilities
Accounts payable, accrued expenses and other current liabilities
Current taxes payable
Other non-current liabilities
Interest payable
Deferred revenue

Net cash provided by (used) in operating activities
Cash flows from investing activities:
Payments under Agreement
BioMarin Pharmaceutical Inc.
CureTech Ltd
Total payments under Agreement
Purchases of short-term investments
Sales or maturities of short-term investments
Purchases of property and equipment
Change in restricted cash
Proceeds from stock option and warrant exercises
Net proceeds from stockholder securities law settlement
Net cash (used in) provided by investing activities

Cash flows from financing activities:
Principal repayment of Convertible Notes
Proceeds from issuance of Convertible Notes, net
Tax withholdings related to net share settlement of performance share awards
Net proceeds from stockholder securities law settlement
Cash settlement of Convertible Notes conversion premium
Proceeds from borrowings under Revolving Credit Facility
Principal repayment of borrowings under Revolving Credit Facility
Financing transaction costs
Excess tax benefits from stock-based compensation
Proceeds from issuance of common stock under equity incentive and stock purchase plans
Reduction of build-to-suit lease obligation
Purchases of short-term investments
Maturities of short-term investments
Net cash (used in) provided by financing activities

Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental disclosures of cash flow information:
Interest
Income taxes, net of refunds
Non-cash investing and financing activities:
Reacquisition of Convertible Notes equity component upon conversion
Fair value of common stock issued for conversion of Convertible Notes
Derecognition of build-to-suit lease asset
Derecognition of build-to-suit lease obligations
Property and equipment expenditures incurred but not yet paid
Stock appreciation rights-reclassification from current liabilities to stockholders' equity
Interest capitalized during construction period for build-to-suit lease transactions
Accrued interest payable forfeited upon conversion of Convertible Notes
Amounts capitalized under build-to-suit lease transactions

Comments